Your browser is no longer supported. Please, upgrade your browser.
Savara Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.40% Shs Outstand60.71M Perf Week-10.26%
Market Cap204.35M Forward P/E- EPS next Y-0.40 Insider Trans176.67% Shs Float45.24M Perf Month-24.89%
Income-49.60M PEG- EPS next Q-0.08 Inst Own22.30% Short Float4.92% Perf Quarter28.68%
Sales0.30M P/S681.16 EPS this Y57.20% Inst Trans10.44% Short Ratio0.51 Perf Half Y45.83%
Book/sh1.06 P/B1.65 EPS next Y-2.60% ROA-44.90% Target Price- Perf Year-22.91%
Cash/sh0.70 P/C2.49 EPS next 5Y- ROE-63.60% 52W Range1.00 - 3.58 Perf YTD52.17%
Dividend- P/FCF- EPS past 5Y45.40% ROI- 52W High-51.12% Beta1.18
Dividend %- Quick Ratio10.40 Sales past 5Y- Gross Margin- 52W Low75.84% ATR0.24
Employees27 Current Ratio10.40 Sales Q/Q- Oper. Margin- RSI (14)45.58 Volatility9.42% 10.59%
OptionableYes Debt/Eq0.00 EPS Q/Q68.70% Profit Margin- Rel Volume0.55 Prev Close1.68
ShortableYes LT Debt/Eq0.39 Earnings- Payout- Avg Volume4.38M Price1.75
Recom1.80 SMA20-8.51% SMA50-5.66% SMA20011.78% Volume2,400,645 Change4.17%
Mar-16-21Initiated Piper Sandler Overweight $7
Mar-15-21Initiated Oppenheimer Outperform $4
Jun-13-19Reiterated H.C. Wainwright Buy $22 → $6
Jun-13-19Downgrade Ladenburg Thalmann Buy → Neutral $21 → $3
Jun-13-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-13-18Resumed ROTH Capital Neutral $12
Jan-03-18Initiated Ladenburg Thalmann Buy $35
Sep-27-17Resumed ROTH Capital Buy $40
Sep-22-17Initiated Jefferies Buy $20
Sep-11-17Initiated JMP Securities Mkt Outperform $20
Apr-09-21 11:12AM  
Mar-30-21 11:49AM  
Mar-21-21 03:46AM  
Mar-18-21 08:55AM  
Mar-16-21 10:40AM  
Mar-15-21 09:32AM  
Mar-11-21 08:57AM  
Mar-10-21 04:49PM  
Feb-05-21 08:32AM  
Jan-21-21 04:24AM  
Dec-10-20 12:02PM  
Nov-24-20 04:15PM  
Nov-11-20 04:05PM  
Nov-05-20 04:20PM  
Sep-11-20 08:05AM  
Sep-09-20 04:05PM  
Sep-08-20 08:05AM  
Sep-04-20 12:47PM  
Sep-03-20 04:05PM  
Aug-25-20 07:42AM  
Aug-06-20 04:02PM  
Aug-05-20 08:05AM  
Jul-30-20 08:05AM  
Jul-05-20 06:11PM  
May-27-20 04:05PM  
May-08-20 08:05AM  
May-07-20 04:05PM  
Apr-30-20 04:05PM  
Apr-15-20 11:26AM  
Apr-02-20 04:05PM  
Mar-30-20 04:05PM  
Mar-23-20 07:53AM  
Mar-12-20 04:05PM  
Mar-11-20 09:23AM  
Mar-05-20 08:05AM  
Jan-16-20 11:21AM  
Jan-06-20 09:14AM  
Jan-02-20 09:30AM  
Dec-30-19 08:05AM  
Dec-20-19 11:51AM  
Dec-19-19 04:18PM  
Dec-03-19 04:05PM  
Nov-27-19 04:05PM  
Nov-26-19 04:05PM  
Nov-18-19 08:05AM  
Nov-15-19 02:45PM  
Nov-13-19 02:45PM  
Nov-12-19 04:05PM  
Nov-11-19 06:15PM  
Nov-07-19 05:50PM  
Oct-31-19 04:05PM  
Oct-17-19 02:45PM  
Oct-15-19 12:42PM  
Oct-11-19 07:15PM  
Oct-07-19 07:30PM  
Oct-03-19 11:00AM  
Oct-02-19 06:00PM  
Sep-18-19 04:15PM  
Sep-02-19 11:39AM  
Aug-08-19 04:02PM  
Jul-31-19 08:02AM  
Jul-15-19 03:49PM  
Jun-25-19 08:52PM  
Jun-20-19 09:45AM  
Jun-19-19 10:29AM  
Jun-13-19 04:02PM  
Jun-12-19 05:48PM  
Jun-10-19 09:03AM  
May-17-19 12:20PM  
May-16-19 11:17AM  
May-15-19 09:00AM  
May-09-19 04:02PM  
May-06-19 08:02AM  
May-02-19 08:02AM  
Apr-09-19 09:00AM  
Apr-02-19 08:00AM  
Apr-01-19 08:00AM  
Mar-13-19 08:52PM  
Mar-12-19 03:18PM  
Mar-06-19 08:00AM  
Mar-04-19 08:00AM  
Feb-06-19 08:00AM  
Jan-16-19 09:29AM  
Dec-21-18 11:18PM  
Dec-19-18 08:00AM  
Nov-16-18 08:00AM  
Nov-07-18 04:02PM  
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pauls MatthewCHIEF EXECUTIVE OFFICERMar 22Buy2.0724,10049,938280,722Mar 22 09:47 PM
Lowrance David LCHIEF FINANCIAL OFFICERMar 15Buy1.4513,79320,00013,793Mar 15 02:47 PM
McCracken Joseph SDirectorMar 15Buy1.4568,96599,999168,337Mar 15 02:46 PM
RAMSAY DAVID ADirectorMar 15Buy1.45689,6551,000,000811,797Mar 15 02:44 PM
Pauls MatthewCHIEF EXECUTIVE OFFICERFeb 22Buy1.7428,70050,038256,622Feb 23 09:48 AM
Elam Nevan CDirectorDec 15Option Exercise0.522,9301,52424,612Dec 17 12:13 PM